REGULATORY

• Japan Eyes June Submission of Immunization Act Bill to Cover Antibody Drugs
  May 18, 2026

• Calls Grow for Japan Version of EHDS at Regulatory Reform Panel
  May 18, 2026

• Japan OKs Coverage for Susmed Insomnia App, Shionogi ADHD Therapy App
  May 15, 2026

• MHLW’s Mori Vows to Make Japan Pharma Market “More Attractive”
  May 15, 2026

• MHLW Official Says US MFN Policy Could Be Taken Up by Chuikyo
  May 15, 2026

• Oncolys’ Telomelysin Up for Japan Panel Review on May 21
  May 15, 2026

• Japan to Launch CEA “Technical Discussions” under MHLW Research Group
  May 14, 2026

• Mounjaro Hit with 25% Price Cut under Japan’s “SPA-SSS” Re-Pricing
  May 14, 2026

• Japan OKs Listing of Ambelvist, Dojolvi, Sohonos, and Finally Inrebic
  May 14, 2026

• Chuikyo Clears NHI Listing for Amchepry, Akuugo, and Zolgensma Intrathecal
  May 14, 2026

• Tepezza, Trodelvy Headed for NHI Price Cuts after CEAs
  May 14, 2026

• Briviact Faces 4.3% Price Cut from August under CEA Scheme
  May 14, 2026

• Chuikyo to Apply Drug Pricing Rules to Ferring’s Adstiladrin
  May 14, 2026

• Japan to Finalize 1st ALS Trial Guidelines This Year to Spur Global Development
  May 13, 2026

• Biosimilar Efficacy Trials Can Be Waived under Certain Conditions: MHLW
  May 13, 2026

• LDP Lawmakers’ League Eyes Broader Push for Domestic API Production
  May 13, 2026

• AstraZeneca’s Oral SERD, MSD RSV Antibody Up for Japan Panel Review on May 25
  May 12, 2026

• Daiichi Sankyo Wins Japan Approval for MMR Vaccine Mimrit
  May 12, 2026

• MHLW Issues Q&A on Conditional Approval System
  May 1, 2026

• Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
  May 1, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »